ロード中...
Seamless Phase I–II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents
PURPOSE: The premise for phase I trials for cytostatic agents is different from that of cytotoxic agents. For cytostatic agents, toxicity and efficacy do not necessarily increase monotonically with increasing dose levels, but likely plateau after they reach maximal toxicity or efficacy. Here, we pro...
保存先:
| 出版年: | Clin Cancer Res |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4391513/ https://ncbi.nlm.nih.gov/pubmed/21135145 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-1262 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|